interventional cardiologist for peripheral dz as well. Also got trained in pharmacology, clinical pharmacology, cell and molecular biology, & translational med
@JACCJournals It is biased to establish “causality” using Mendelian (so called ) Randomization Study due to its intrinsic weakness to infer unknown with limited knowns. The way to establish causality is to check the effects after Lp(a) is specifically inhibited. Let’s wait for the trials
@NEJM NEJM publications often appear later on PubMed and are not synchronized with PubMed unlike many other journals, although many institutions provide library access to NEJM through PubMed.
Thank you for publishing our article!@JACCJournals @UNCCardiology@UNCDeptMedicine@GilbertTangMD#JACCCaseReports Regadenoson is considered to be safe for cardiac stress test. However as FDA warns, serious side effects including STEM may happen, although rare. Awareness !
Raising Awareness of ST-Segment Elevation Myocardial Infarction Triggered by Intravenous Regadenoson for Cardiac Stress Testing | JACC: Case Reports https://t.co/4sAtvpeqAM
Raising Awareness of ST-Segment Elevation Myocardial Infarction Triggered by Intravenous Regadenoson for Cardiac Stress Testing | JACC: Case Reports https://t.co/Q5hiX1hrcu
@CircAHA It is reasonable to say that it is a biased overstatement to say Lp(a) is causal for those CV diseases based on Mendelian randomization trials or epidemiological data until data showing inhibiting Lp(a) in different ways reduces CV events, with hard endpoints, are available.
@CircAHA It is reasonable to say that it is a biased overstatement to say Lp(a) is causal for those CV diseases based on Mendelian randomization trials or epidemiological data until data showing inhibiting Lp(a) in different ways reduces CV events, with hard endpoints, are available.
@JWatch@SheaHogan7 Until clinical outcome (ideally “hard”endpoints, instead of composite w soft ones or surrogate endpoints) data on Lp(a) specific inhibitor are available, it is safe to say Lp(a) is no more than a parameter to gauge the risk of ASCVD.